PolyPid (NASDAQ:PYPD) — Market Cap & Net Worth
Market Cap & Net Worth: PolyPid (PYPD)
PolyPid (NASDAQ:PYPD) has a market capitalization of $77.73 Million ($77.73 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20091 globally and #4522 in its home market, demonstrating a 1.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PolyPid's stock price $4.29 by its total outstanding shares 18204002 (18.20 Million). See how much does PolyPid reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
PolyPid Market Cap History: 2020 to 2026
PolyPid's market capitalization history from 2020 to 2026. Data shows change from $5.41 Billion to $78.10 Million (-55.14% CAGR).
Index Memberships
PolyPid is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #571 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1944 of 3165 |
Weight: PolyPid's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PolyPid Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PolyPid's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PYPD by Market Capitalization
Companies near PolyPid in the global market cap rankings as of August 3, 2026.
Key companies related to PolyPid by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
PolyPid Historical Marketcap From 2020 to 2026
Between 2020 and today, PolyPid's market cap moved from $5.41 Billion to $ 78.10 Million, with a yearly change of -55.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $78.10 Million | -1.15% |
| 2025 | $79.01 Million | +42.76% |
| 2024 | $55.34 Million | -20.00% |
| 2023 | $69.18 Million | -81.84% |
| 2022 | $380.92 Million | -87.85% |
| 2021 | $3.13 Billion | -42.02% |
| 2020 | $5.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of PolyPid was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.73 Million USD |
| MoneyControl | $77.73 Million USD |
| MarketWatch | $77.73 Million USD |
| marketcap.company | $77.73 Million USD |
| Reuters | $77.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more